论文部分内容阅读
目的:探讨检测血清CA125对上皮性卵巢癌的临床价值。方法:复习84例上皮性卵巢癌患者手术前后血清CA125水平,并结合临床病理相关资料进行分析。结果:术前血清CA125在浆液性癌和内膜样癌中明显高于黏液性癌(P<0.01),晚期明显高于早期(P<0.05),生存期大于5年者明显低于生存期小于5年者(P<0.01);术后复发者血清CA125水平明显高于未复发者(P<0.01),CA125半衰期>20天的复发率显著高于≤20天者(P<0.01)。结论:上皮性卵巢癌患者术前测定血清CA125水平可初步判断组织学类型、肿瘤分期并可预测患者生存期;术后监测血清CA125水平可及时发现复发者。
Objective: To investigate the clinical value of detecting serum CA125 in epithelial ovarian cancer. Methods: The levels of serum CA125 in 84 patients with epithelial ovarian cancer before and after operation were reviewed and analyzed with clinicopathological data. Results: The preoperative serum CA125 was significantly higher in serous carcinoma and endometrial carcinoma than in mucinous carcinoma (P <0.01), and significantly higher in early stage than in early stage (P <0.05). The survival time was significantly lower than that in 5 years (P <0.01). The serum CA125 level in postoperative recurrence patients was significantly higher than that in non-recurrence patients (P <0.01). The recurrence rate of CA125 with half life> 20 days was significantly higher than that in patients ≤20 days (P <0.01). Conclusion: The level of serum CA125 in patients with epithelial ovarian cancer can be preliminarily determined by histological type, tumor stage and prognosis. The serum levels of CA125 can be detected in patients with epithelial ovarian cancer after operation.